Yilian Biopharma

MediLink Therapeutics, also known as Yilian Biopharma, is a clinical-stage biotechnology company specializing in the development of next-generation antibody-drug conjugates (ADCs) for oncology. Founded in 2020 and headquartered in Suzhou, China, the company utilizes its proprietary TMALIN (Tumor Microenvironment Activable Linker-payload) platform to create therapies with improved therapeutic windows and enhanced efficacy. MediLink has established significant global partnerships, including multi-billion dollar licensing agreements with BioNTech for YL202 and Roche for YL211. Its lead candidate, YL201, is currently in Phase 1/2 clinical trials for various solid tumors, including non-small cell lung cancer and breast cancer. The company is supported by a strong investor base, including Qiming Venture Partners and Loyal Valley Capital, and maintains research facilities in Shanghai and Boston.